OBJECTIVE: To critically review the theoretical and actual risks and benefits of accelerated partial breast irradiation (APBI) after breast-conserving surgery. SUMMARY BACKGROUND DATA: Because of rapid evolution of radiation therapy techniques related to brachytherapy and three-dimensional conformal radiation therapy, APBI has very recently come to the forefront as a potential local treatment option for women with breast cancer. This review aims to give an overview of the biologic rationale for APBI techniques, and benefits and limitations of APBI techniques. METHODS: The authors reviewed the currently available published world medical literature on breast-conserving surgery with and without postoperative irradiation; all studies involving partial breast irradiation, including brachytherapy, for breast cancer; and currently accruing and planned APBI trials. The focus of this review was the early results of treatment in terms of toxicity, complications, cosmesis, and local control. RESULTS: On average, approximately 3% of patients treated with breast-conserving surgery will have an in-breast local recurrence away from the original lumpectomy site with or without postoperative standard whole-breast irradiation. The results of phase I-II studies involving approximately 500 patients treated with APBI after breast-conserving surgery have been published. Although many of the studies have limited long-term follow-up and potential selection bias, early results suggest that toxicity, cosmesis, and local control are comparable to outcomes seen after breast-conserving surgery followed by standard whole-breast irradiation. CONCLUSIONS: Recent advances in radiation delivery and published series of partial breast irradiation support large randomized trials comparing APBI with standard whole-breast irradiation after breast-conserving surgery.
OBJECTIVE: To critically review the theoretical and actual risks and benefits of accelerated partial breast irradiation (APBI) after breast-conserving surgery. SUMMARY BACKGROUND DATA: Because of rapid evolution of radiation therapy techniques related to brachytherapy and three-dimensional conformal radiation therapy, APBI has very recently come to the forefront as a potential local treatment option for women with breast cancer. This review aims to give an overview of the biologic rationale for APBI techniques, and benefits and limitations of APBI techniques. METHODS: The authors reviewed the currently available published world medical literature on breast-conserving surgery with and without postoperative irradiation; all studies involving partial breast irradiation, including brachytherapy, for breast cancer; and currently accruing and planned APBI trials. The focus of this review was the early results of treatment in terms of toxicity, complications, cosmesis, and local control. RESULTS: On average, approximately 3% of patients treated with breast-conserving surgery will have an in-breast local recurrence away from the original lumpectomy site with or without postoperative standard whole-breast irradiation. The results of phase I-II studies involving approximately 500 patients treated with APBI after breast-conserving surgery have been published. Although many of the studies have limited long-term follow-up and potential selection bias, early results suggest that toxicity, cosmesis, and local control are comparable to outcomes seen after breast-conserving surgery followed by standard whole-breast irradiation. CONCLUSIONS: Recent advances in radiation delivery and published series of partial breast irradiation support large randomized trials comparing APBI with standard whole-breast irradiation after breast-conserving surgery.
Authors: Gregory K Edmundson; Frank A Vicini; Peter Y Chen; Christina Mitchell; Alvaro A Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-15 Impact factor: 7.038
Authors: U Veronesi; E Marubini; L Mariani; V Galimberti; A Luini; P Veronesi; B Salvadori; R Zucali Journal: Ann Oncol Date: 2001-07 Impact factor: 32.976
Authors: K L Baglan; A A Martinez; R C Frazier; V R Kini; L L Kestin; P Y Chen; G Edmundson; E Mele; D Jaffray; F A Vicini Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: U Veronesi; R Orecchia; A Luini; G Gatti; M Intra; S Zurrida; G Ivaldi; G Tosi; M Ciocca; A Tosoni; F De Lucia Journal: Eur J Cancer Date: 2001-11 Impact factor: 9.162
Authors: Roland Reitsamer; Florentia Peintinger; Felix Sedlmayer; Michael Kopp; Walter Cimpoca; Christian Menzel Journal: Ann Surg Date: 2005-07 Impact factor: 12.969
Authors: Jacqueline S Jeruss; Henry M Kuerer; Peter D Beitsch; Frank A Vicini; Martin Keisch Journal: Ann Surg Oncol Date: 2010-06-25 Impact factor: 5.344
Authors: Kevin Albuquerque; Dina Tell; Philip Lobo; Linda Millbrandt; Herbert L Mathews; Linda Witek Janusek Journal: BMC Cancer Date: 2012-06-18 Impact factor: 4.430
Authors: Parminder S Basran; Sergei Zavgorodni; Tanya Berrang; Ivo A Olivotto; Wayne Beckham Journal: Radiat Oncol Date: 2010-12-16 Impact factor: 3.481